New Delhi : Ranbaxy Laboratories declined to comment on reports from Brussels that European Union anti-trust regulators may fine it for allegedly blocking the entry of cheaper generic medicines in the EU. Reports said that Ranbaxy was among the nine companies that are to be fined. When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point”. Other firms named in the reports were Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers. Shares of Ranbaxy fell by 3.49% to end at Rs 362.35 apiece at the BSE on Monday.